Literature DB >> 31790614

Plasmatic exosomes from prostate cancer patients show increased carbonic anhydrase IX expression and activity and low pH.

Mariantonia Logozzi1, Davide Mizzoni1, Clemente Capasso2, Sonia Del Prete2, Rossella Di Raimo1, Mario Falchi3, Daniela F Angelini4, Alessandro Sciarra5, Martina Maggi5, Claudiu T Supuran6, Stefano Fais1.   

Abstract

Acidity, hypoxia and increased release of exosomes are severe phenotypes of tumours. The regulation of pH in tumours involves the interaction of several proteins, including the carbonic anhydrases which catalyze the formation of bicarbonate and protons from carbon dioxide and water. Among CA isoforms, CA IX is over-expressed in a large number of solid tumours, conferring to cancer cells a survival advantage in hypoxic and acidic microenvironment, but there isn't evidence that CA IX expression could have a real clinical impact. Therefore, in this study for the first time the expression and activity of CA IX have been investigated in the plasmatic exosomes obtained from patients with prostate carcinoma (PCa). For this purpose, the study was performed through different methodological approaches, such as NTA, western blot analysis, enzyme activity assay, Nanoscale flow cytometry, ELISA, confocal microscopy. The results showed that PCa exosomes significantly overexpressed CA IX levels and related activity as compared to healthy donors. Furthermore, CA IX expression and activity were correlated to the exosome intraluminal pH, demonstrating for the first time that PCa exosomes are acidic. Our data suggest the possible use of the exosomal CA IX expression and activity as a biomarker of cancer progression in PCa.

Entities:  

Keywords:  Acidic tumour microenvironment; biomarker; carbonic anhydrase IX; plasmatic exosomes; prostate cancer

Mesh:

Substances:

Year:  2020        PMID: 31790614      PMCID: PMC6896418          DOI: 10.1080/14756366.2019.1697249

Source DB:  PubMed          Journal:  J Enzyme Inhib Med Chem        ISSN: 1475-6366            Impact factor:   5.051


  37 in total

1.  The Structure of Carbonic Anhydrase IX Is Adapted for Low-pH Catalysis.

Authors:  Brian P Mahon; Avni Bhatt; Lilien Socorro; Jenna M Driscoll; Cynthia Okoh; Carrie L Lomelino; Mam Y Mboge; Justin J Kurian; Chingkuang Tu; Mavis Agbandje-McKenna; Susan C Frost; Robert McKenna
Journal:  Biochemistry       Date:  2016-08-05       Impact factor: 3.162

2.  Exosomes released in vitro from Epstein-Barr virus (EBV)-infected cells contain EBV-encoded latent phase mRNAs.

Authors:  Andrea Canitano; Giulietta Venturi; Martina Borghi; Maria Grazia Ammendolia; Stefano Fais
Journal:  Cancer Lett       Date:  2013-05-16       Impact factor: 8.679

Review 3.  Extracellular acidity and increased exosome release as key phenotypes of malignant tumors.

Authors:  Mariantonia Logozzi; Enrico Spugnini; Davide Mizzoni; Rossella Di Raimo; Stefano Fais
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

4.  Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis.

Authors:  Elena Andreucci; Silvia Peppicelli; Fabrizio Carta; Giulia Brisotto; Eva Biscontin; Jessica Ruzzolini; Francesca Bianchini; Alessio Biagioni; Claudiu T Supuran; Lido Calorini
Journal:  J Mol Med (Berl)       Date:  2017-09-19       Impact factor: 4.599

Review 5.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

6.  The proteoglycan region of the tumor-associated carbonic anhydrase isoform IX acts as anintrinsic buffer optimizing CO2 hydration at acidic pH values characteristic of solid tumors.

Authors:  Alessio Innocenti; Silvia Pastorekova; Jaromir Pastorek; Andrea Scozzafava; Giuseppina De Simone; Claudiu T Supuran
Journal:  Bioorg Med Chem Lett       Date:  2009-08-31       Impact factor: 2.823

Review 7.  Carbonic anhydrase IX inhibitors in cancer therapy: an update.

Authors:  Claudiu T Supuran; Jean-Yves Winum
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 8.  Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: Three for the price of one.

Authors:  Claudiu T Supuran; Vincenzo Alterio; Anna Di Fiore; Katia D' Ambrosio; Fabrizio Carta; Simona Maria Monti; Giuseppina De Simone
Journal:  Med Res Rev       Date:  2018-04-10       Impact factor: 12.944

Review 9.  Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery?

Authors:  Katsuyuki Kusuzaki; Takao Matsubara; Hiroaki Murata; Mariantonia Logozzi; Elisabetta Iessi; Rossella Di Raimo; Fabrizio Carta; Claudiu T Supuran; Stefano Fais
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

10.  Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin.

Authors:  Cristina Federici; Francesco Petrucci; Stefano Caimi; Albino Cesolini; Mariantonia Logozzi; Martina Borghi; Sonia D'Ilio; Luana Lugini; Nicola Violante; Tommaso Azzarito; Costanza Majorani; Daria Brambilla; Stefano Fais
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

View more
  15 in total

1.  Multicellular tumor spheroids of LNCaP-Luc prostate cancer cells as in vitro screening models for cytotoxic drugs.

Authors:  Elodie Jouberton; Aurélien Voissiere; Frédérique Penault-Llorca; Florent Cachin; Elisabeth Miot-Noirault
Journal:  Am J Cancer Res       Date:  2022-03-15       Impact factor: 6.166

Review 2.  Alternating exosomes and their mimetics as an emergent strategy for targeted cancer therapy.

Authors:  Lokesh Chandra Mishra; Utkarsh Pandey; Abhikarsh Gupta; Jyotsna Gupta; Monal Sharma; Gauri Mishra
Journal:  Front Mol Biosci       Date:  2022-08-10

Review 3.  Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment.

Authors:  Akhil Srivastava; Shipra Rathore; Anupama Munshi; Rajagopal Ramesh
Journal:  Semin Cancer Biol       Date:  2022-02-19       Impact factor: 17.012

Review 4.  Exosomal biomarkers for cancer diagnosis and patient monitoring.

Authors:  Amy Makler; Waseem Asghar
Journal:  Expert Rev Mol Diagn       Date:  2020-02-20       Impact factor: 5.225

Review 5.  Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.

Authors:  Stefano Salciccia; Anna Laura Capriotti; Aldo Laganà; Stefano Fais; Mariantonia Logozzi; Ettore De Berardinis; Gian Maria Busetto; Giovanni Battista Di Pierro; Gian Piero Ricciuti; Francesco Del Giudice; Alessandro Sciarra; Peter R Carroll; Matthew R Cooperberg; Beatrice Sciarra; Martina Maggi
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 6.  Immunocapture-based ELISA to characterize and quantify exosomes in both cell culture supernatants and body fluids.

Authors:  Mariantonia Logozzi; Rossella Di Raimo; Davide Mizzoni; Stefano Fais
Journal:  Methods Enzymol       Date:  2020-07-09       Impact factor: 1.600

Review 7.  Potential roles and prognostic significance of exosomes in cancer drug resistance.

Authors:  Mostafa Mostafazadeh; Nasser Samadi; Houman Kahroba; Behzad Baradaran; Sanya Haiaty; Mohammad Nouri
Journal:  Cell Biosci       Date:  2021-01-06       Impact factor: 7.133

8.  Targeting the pH Paradigm at the Bedside: A Practical Approach.

Authors:  Tomas Koltai
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

Review 9.  Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma.

Authors:  Stefano Burgio; Leila Noori; Antonella Marino Gammazza; Claudia Campanella; Mariantonia Logozzi; Stefano Fais; Fabio Bucchieri; Francesco Cappello; Celeste Caruso Bavisotto
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

Review 10.  Advances in the discovery of exosome inhibitors in cancer.

Authors:  Huarui Zhang; Jun Lu; Jin Liu; Ge Zhang; Aiping Lu
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.